27 Apr
2023
10:01 E.S.T.

Cellectis to Report First Quarter 2023 Financial Results on May 4, 2023

Read more

24 Apr
2023
11:39 E.S.T.

Cellectis Implements CLLS52 for the First Time in the Clinic with Sanofi’s Alemtuzumab

Read more

17 Apr
2023
02:00 E.S.T.

Cellectis Presents Preclinical Data on TALEN®-edited MUC1 CAR T-cells to Enhance Efficacy in Targeting Triple Negative Breast Cancer at the American Association for Cancer Research (AACR) Annual Meeting

Read more

11 Apr
2023
16:30 E.S.T.

Cellectis Announces Dosing of the First Patient in Europe with its In-house Manufactured Product Candidate UCART22

Read more

04 Apr
2023
16:30 E.S.T.

Cellectis enters into warrant agreement with the European Investment Bank related to credit facility agreement and announces the drawdown of the first tranche of €20 million

Read more

14 Mar
2023
17:00 E.S.T.

Cellectis Announces Poster Presentation on TALEN®-edited MUC1 CAR T-cells Targeting Triple Negative Breast Cancer at the American Association of Cancer Research (AACR) Annual Meeting

Read more

08 Mar
2023
16:45 E.S.T.

Cellectis Provides Business Update and Reports Fourth Quarter and Full Year 2022 Financial Results

Read more

06 Mar
2023
16:30 E.S.T.

Calyxt, Inc. Reports its Fourth Quarter 2022 Financial Results and Provides Corporate Update

Read more

01 Mar
2023
16:30 E.S.T.

Cellectis to Report Fourth Quarter and Year-End 2022 Financial Results on March 8, 2023

Read more

07 Feb
2023
17:32 E.S.T.

Cellectis Announces Closing of Global Offering and Exercise of Underwriters’ Option to Purchase Additional Shares

Read more